Skip to content

AIM ImmunoTech Inc. (AIM) — WACC Analysis

WACC Breakdown

AIM ImmunoTech Inc. (AIM) has a weighted average cost of capital (WACC) of 15.8%. The cost of equity is 9.4%, derived from a beta of 1.00 and a risk-free rate of 5.2%. The after-tax cost of debt is 25.7%. The capital structure is 61.2% equity and 38.8% debt.

Interpretation

A WACC of 15.8% indicates that the market perceives AIM ImmunoTech Inc. as higher-risk, requiring a greater return to compensate investors.

Investors can compare AIM's WACC of 15.8% against industry peers to gauge its relative financing costs. A beta of 1.00 reflects the stock's volatility relative to the broader market.

DeepViews
VALUATION

AIM WACC: 15.76% for AIM ImmunoTech Inc.

Current inputs imply a 9.45% cost of equity and a 25.73% pre-tax cost of debt. Use this discount rate as a starting point for DCF validation.

[01]Current Market Data
Loading market data...
[02]
WACC Calculation Process
1
Market Data Loaded
2
Company Data Fetched
3
Beta Calculated (5Y)
4
Inputs Auto-Populated
5
WACC Calculated
[03]
Step 2: Enter Ticker Symbol
Quick search:
Step 4: Review Auto-Populated WACC Inputs

Values are automatically populated from real data. You can adjust them manually if needed.

4.30%
1.000
4.23%
5.00%
21.00%
70.00%
Debt: 30.00%Equity: 70.00%

Please enter a valid company ticker to calculate WACC

AIM ImmunoTech Inc. Common Stock (AIM) WACC Results
Weighted Average Cost of Capital
15.76%
Cost of Equity
9.45%
Risk-Free Rate5.22%
Beta1.00
Market Risk Premium4.23%
Cost of Debt
25.73%
Pre-Tax Cost of Debt25.73%
Tax Rate0.00%
Tax Shield0.00%
Capital Structure
Equity: 61.22%($7.18M)
Debt: 38.78%($4.55M)
Equity Component
5.79%
61.22% × 9.45%
Debt Component
9.98%
38.78% × 25.73%

AIM ImmunoTech Inc. (AIM) WACC in context

AIM ImmunoTech Inc. (AIM) currently screens with an estimated WACC of 15.76%. That blends a 9.45% cost of equity, a 25.73% pre-tax cost of debt, and a 61.22% equity weight into the discount rate you would typically use in a DCF model.

screens as a relatively high discount rate, which makes valuation more sensitive to execution and capital structure risk.

What AIM WACC implies

A 15.76% discount rate screens as a relatively high discount rate, which makes valuation more sensitive to execution and capital structure risk.

How this page calculates AIM

This page combines CAPM-based cost of equity with SEC-derived debt and capital structure inputs. The current beta is 1.00 and equity accounts for 61.22% of capital.

What to do next

Validate business quality on the company page, then carry the same discount-rate assumptions into the DCF page to test fair value sensitivity.

Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.

AIM WACC: 15.76% — AIM ImmunoTech Inc. Cost of Capital (October 2026) | DeepViews